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Abstract
The role of CD8 T cells in anti-tuberculosis immunity in humans remains unknown, and studies of CD8 T cell–mediated
protection against tuberculosis in mice have yielded controversial results. Unlike mice, humans and nonhuman primates share
anumberofimportantfeaturesofthe immunesystemthatrelatedirectlytothespecificityand functionsofCD8Tcells,such as
the expression of group 1 CD1 proteins that are capable of presenting Mycobacterium tuberculosis lipids antigens and the
cytotoxic/bactericidal protein granulysin. Employing a more relevant nonhuman primate model of human tuberculosis, we
examined the contribution of BCG- or M. tuberculosis-elicited CD8 T cells to vaccine-induced immunity against tuberculosis.
CD8 depletion compromised BCG vaccine-induced immune control of M. tuberculosis replication in the vaccinated rhesus
macaques. Depletion of CD8 T cells in BCG-vaccinated rhesus macaques led to a significant decrease in the vaccine-induced
immunity against tuberculosis. Consistently, depletion of CD8 T cells in rhesus macaques that had been previously infected
with M. tuberculosis and cured by antibiotic therapy also resulted in a loss of anti-tuberculosis immunity upon M. tuberculosis
re-infection. The current study demonstrates a major role for CD8 T cells in anti-tuberculosis immunity, and supports the view
that CD8 T cells should be included in strategies for development of new tuberculosis vaccines and immunotherapeutics.
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Introduction
Tuberculosis remains one of the major causes of global
mortality, and has become increasingly prevalent and deadly as
a result of HIV/AIDS pandemic and the emergence of extensively
drug resistant (XDR) strains of M. tuberculosis [1]. Elucidating the
relevant components of anti-tuberculosis immunity is therefore of
critical importance and urgency to facilitate the development of
safe and effective vaccines for the global battle against tuberculosis.
The attenuated Mycobacterium bovis strain Bacille Calmette-Guerin
(BCG) is currently the sole vaccine for tuberculosis that is
approved for use in humans. BCG vaccination has been shown
to induce protection against severe tuberculosis in children and
nonhuman primates, but it is inconsistent or ineffective at
conferring protection against tuberculosis in adults who have
been vaccinated early in life [2,3,4,5,6].
Although it is widely accepted that CD4 T cells play a critical role
in the abilityof humansand experimentalanimals to resist activeM.
tuberculosis infection[7],thecontributionofCD8T cellstonaturalor
BCG-induced immunity against tuberculosis remains unclear.
Some in vivo studies in mice and bovines or in vitro work in humans
provide evidence supporting the contribution of CD8 T cells to
immunity against tuberculosis [8,9,10,11,12,13,14,15,16,17,18],
whereas a number of studies in mouse models of tuberculosis have
argued against a significant role for CD8 T cells in the control of
primary M. tuberculosis infection [19,20,21,22,23,24,25]. However, it
is likely that the mouse model of tuberculosis does not accurately
reflect the complete picture of how protective immune responses
against tuberculosis develop in humans, and better models of this
disease are neededto enable a full understandingof this process. We
propose that nonhuman primates should provide more relevant
models for evaluating a role of human CD8+ T cells in BCG
vaccine-induced immunity against tuberculosis [6,26,27,28,29,30].
Unlike mice and other rodents studied to date, rhesus macaques
share with humans a number of important features of the immune
system that relate directly to the specificity and functions of CD8 T
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capable of presenting M. tuberculosis lipids antigens and the
cytotoxic/bactericidal protein granulysin [31,32]. Importantly, we
and others have shown that disease course and pathology in M.
tuberculosis-infected macaques resemble human tuberculosis, and
that vaccine-induced immunity to tuberculosis can be experimen-
tally evaluated in rhesus and cynomolgus macaques
[6,28,29,33,34]. Although the importance of CD4 T cells in
nonhuman primate models of tuberculosis has been reported, data
are currently lacking on the role of CD8 T cells [35,36].
Results
Anti-CD8 Ab treatment of BCG-vaccinated rhesus
macaques induced profound depletion of CD8
lymphocytes and BCG-elicited CD8 T cells during
pulmonary M. tuberculosis infection
To directly examine the importance of CD8 T cells in BCG
vaccine-induced anti-tuberculosis immunity, six BCG-vaccinated
macaques were treated with depleting anti-CD8 antibody, cM-
T807 [37] at the same time that they received pulmonary
inoculation with M. tuberculosis. Pulmonary M. tuberculosis infection
was introduced by bronchoscope-guided inoculation of 3000 CFU
of M. tuberculosis into the right caudal lobe [29]. As controls, six
BCG-vaccinated moneys were treated similarly with isotype-
matched human IgG at the time of infection with M. tuberculosis,
and six unvaccinated macaques (naı ¨ve controls) were treated with
saline at the time pulmonary M. tuberculosis was introduced.
Treatment with depleting anti-CD8 Ab resulted in profound
depletion of CD8 cells during M. tuberculosis infection, with
CD3+CD8+ T cells and CD32CD8+ cells falling to barely
detectable levels in blood and BAL fluid at 1–4 weeks after the
simultaneous anti-CD8 Ab treatment and M. tuberculosis infection
(Fig. 1A). Even at 7 weeks after the anti-CD8 Ab treatment, CD8
T cells remained partially depleted (Fig. 1A). Consistently, peptide
antigen-specific IFNc-producing CD8 T effector cells also became
undetectable early after the simultaneous CD8 depletion and M.
tuberculosis infection (Fig. 1B). In contrast, the macaques treated
with the nonspecific isotype matched control Ab exhibited
increased percentages and numbers of CD8 T cells, including
peptide-specific CD8 T effector cells, after the M. tuberculosis
infection (Fig. 1A,1B). Thus, we concluded that this method of
CD8 T cell depletion was suitable for evaluating the impact of
previously immunized CD8 T cells on the progression and
outcome of pulmonary tuberculosis infection in the macaque
model.
CD8 depletion compromised BCG vaccine-induced
immune control of M. tuberculosis replication in the
vaccinated macaques
To determine the impact of depletion of CD8 lymphocytes
including BCG-elicited CD8 T cells on immunity to tuberculosis
in the rhesus macaque model, we evaluated four aspects of vaccine
efficacy: (i) severe clinical manifestations such as marked changes
in temperature, progressive coughing, dispnea/distress, anorexia,
altered consciousness or weight loss during a 2-month follow-up;
(ii) bacterial colony counts in BAL fluid at various times after M.
tuberculosis infection and in lung tissues at necropsy; (iii) gross
pathology of the lungs and other thoracic and extrathoracic organs
at necropsy; (iv) histologic evaluation of tissues for granulomas and
other microscopic lesions. None of the macaques in any of the
control or treatment groups developed fatal clinical tuberculosis or
significant loss of body weight during 2-months of follow-up. This
was consistent with earlier reports that Chinese rhesus macaques
were more resistant to infections than Indian rhesus macaques,
and that adult animals were less susceptible to fatal tuberculosis
than juveniles [6,27,38]. Nevertheless, the CD8 Ab-treated group
of BCG-vaccinated macaques showed significantly higher bacterial
counts in BAL fluids than the IgG isotype control group at 42 days
after M. tuberculosis infection (Fig. 2A). In addition, the CD8 Ab-
treated group also had significantly higher bacterial CFU counts in
the lung tissues in the right caudal lobe (M. tuberculosis infection site)
and distant right middle lobe than the isotype IgG-treated group
(Fig. 2B). These results suggested that CD8 T cells contributed to
BCG vaccine-induced immune control of M. tuberculosis replication
in the vaccinated macaques.
Depletion of CD8 T cells in BCG-vaccinated rhesus
macaques led to a significant decrease in the vaccine-
induced immunity against tuberculosis
The next critical question regarding the contribution of CD8 T
cells to BCG vaccine-induced immunity against tuberculosis was
whether depletion of CD8 lymphocytes in BCG-vaccinated
macaques led to more severe tuberculosis lesions. To address this,
we performed complete necropsy studies 2 months after M.
tuberculosis infection of three groups of macaques. The gross
pathology was evaluated in detail in a quantitative fashion using a
previously described scoring systems [6,28,29,33], and then
compared among the three groups of M. tuberculosis-infected
macaques. The isotype control IgG-treated BCG-vaccinated
macaques exhibited apparent protection against tuberculosis
compared to the naı ¨ve saline-treated group (Fig. 3). For these
macaques with intact BCG-elicited CD8 T cells, M. tuberculosis
infection appeared to be well contained by individual granulomas
predominantly at the primary infection site in the right caudal lobe
(Fig. 3A). In contrast, the CD8 Ab-treated group of BCG-
vaccinated macaques exhibited a reduced containment of
tuberculosis lesions in the infection site. CD8 Ab-treated macaques
showed greater numbers of lung lobes showing extensive
coalescing granulomas than isotype IgG-treated control animals
Author Summary
Tuberculosis, HIV/AIDS and malaria remain top killers
worldwide. Cell-mediated immune responses play a crucial
role in immunity against tuberculosis. While CD4 T cells are
well described for their protection against tuberculosis,
little is known about the role of human CD8 T cells in anti-
tuberculosis immunity. Studies done to date in mice have
yielded conflicting results regarding the role of mouse CD8
T cells in tuberculosis. Since there are considerable
differences in CD8 T cell biology between mice and
primates including humans and macaques, studies in
humans or macaques are crucial for clarifying human CD8
T cell–mediated immunity against tuberculosis. Thus, we
used a macaque tuberculosis model to examine the
contribution of CD8 T cells to vaccine-induced immunity
against tuberculosis. We found that CD8 T cells play a role
in BCG vaccine-induced immune control of Mycobacterium
tuberculosis replication and in the vaccine-induced immu-
nity against tuberculosis. Consistently, memory CD8 T cells
also play a crucial role in anti-tuberculosis immunity upon
M. tuberculosis re-infection. The findings in the current
study provide evidence that human CD8 T cells are of
importance for anti-tuberculosis immunity, and support
the view that CD8 T cells should be targeted for
development of new tuberculosis vaccines and immu-
notherapeutics.
Role of CD8 T Cells in Anti-Tuberculosis Immunity
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more lobes with severe/extensive caseating and miliary lesions or
caseation pneumonia than the isotype IgG-treated controls
(p,0.05, Fig. 3A). Tuberculosis lesions in the CD8 Ab-treated
macaques were more likely distributed or disseminated in other
lobes or opposite lungs and hilar lymph nodes/pleural (Fig. 3A).
Furthermore, depletion of CD8 lymphocytes led to systemic
dissemination of tuberculosis, as grossly apparent granulomas were
identified in extra-thoracic organs in five of 6 macaques treated
with anti-CD8 Ab. When total scores of gross tuberculosis lesions
were calculated for individual macaques, and compared among
the three groups of animals, we found that the CD8 Ab-treated
group developed significantly worse gross tuberculosis lesions than
the isotype IgG-treated group (p,0.05, Fig. 3B).
The severity of tuberculosis following depletion of CD8
lymphocytes was further evaluated at the microscopic level, which
revealed that depletion of CD8 lymphocytes during M. tuberculosis
infection led to changes in the organization and cellular
composition of granulomas. In the isotype control IgG-treated
macaques with intact CD8 T cells, M. tuberculosis infection was
usually contained by well-organized granulomas infiltrated by
numerous lymphocytes and some neutrophils (Fig. 3C). However,
in the CD8 Ab-treated macaques, lymphocytic infiltration was
reduced and necrosis was more pronounced, especially in the lungs
(Fig. 3C). Furthermore, microscopic scanning of a series of tissue
sections derived from extrathoracic organs revealed that five of six
CD8 Ab-treated BCG-vaccinated macaques had a number of
granulomatous lesions in the spleen, whereas only one of six
isotype control IgG-treated macaques displayed microscopic
granulomas in the spleen. All naı ¨ve macaques developed multiple
granulomatous lesions in spleens and livers (Fig. 3C).
Depletion of CD8 T cells in macaques that had been
previously infected with M. tuberculosis and cured by
antibiotic therapy also resulted in a loss of anti-
tuberculosis immunity upon M. tuberculosis re-infection
Finally, we sought to examine whether CD8 memory T cells
resulting from prior M. tuberculosis infection were also important for
anti-tuberculosis immunity. This question is directly relevant to the
development of novel vaccines that are based on attenuated M.
tuberculosis mutants with virulence gene deletion or other modifica-
tions [39,40], and also is important for understanding the potential
immunological defects that allowre-infectionwithM.tuberculosis and
reactivation of latent tuberculosis. To generate M. tuberculosis-
immunized animals with anti-tuberculosis immune memory, we
made use of BCG-vaccinated juvenile rhesus macaques who
exhibited rapid recall T cell responses and survived fatal
tuberculosis for 2.5 months after aerosol challenge with 400 CFU
M. tuberculosis. Under these conditions, unimmunized naı ¨ve control
macaques consistently became moribund due to development of
early fatal tuberculosis [6]. These M. tuberculosis-exposed macaques
that had transient low levels of bacillus but no evidence of active
tuberculosis after the challenge were treated daily for 3 months with
a regimen of anti-tuberculosis drugs (5 mg/kg Isoniazid plus and
15 mg/kg Pyrazinamide), and then rested for 2 months during
whichtheyshowednoevidenceofdetectablebacilliinrepeatedlung
Figure 2. Depletion of CD8 lymphocytes resulted in a significant decrease in BCG-induced immune control of M. tuberculosis. (A) CD8
Ab-treated macaquesexhibited higherlevelsof bacilli in BALfluid than isotype IgG-treated macaquesafter pulmonary M. tuberculosis infection. Dataare
means +/2 SEM of CFU counts/10 ml BAL fluid derived from 6 macaques for each group; * indicates p,0.05 for a comparison between the CD8 Ab-
treated and isotype IgG-treated group. (B) CD8 Ab-treated macaques showed significantly higher levels of bacilli organisms in lung tissues than isotype
control macaques after pulmonary M. tuberculosis infection. Data are mean values with SEM error bars of CFU counts/1 ml lung tissue homogenates
derived from 6 macaques for each group. Rt, right; Lt, left. Note that right caudal lobe was the M. tuberculosis infection site for each macaque; *, p,0.05
(by both ANOVA and nonparametric t test) for a comparison between the CD8 Ab-treated and isotype control IgG-treated groups.
doi:10.1371/journal.ppat.1000392.g002
Figure 1. CD8 Ab treatment of BCG-vaccinated macaques resulted in profound depletion of CD8 lymphocytes and mycobacterium-
specific CD8 T effector cells during M. tuberculosis infection. (A) Flow cytometry data showed that anti-CD8 Ab-treated BCG-vaccinated
macaques, but not isotype control IgG-treated BCG-vaccinated or naı ¨ve saline-treated macaques, exhibited marked decreases in percentages and
absolute (data not shown) numbers of CD3+CD8+ and CD32CD8+ lymphocytes in blood (upper left) and BAL fluid (upper right) during M.
tuberculosis infection. Means for six animals are shown for each group, and error bars represent SEM. Arrows indicate the times for the treatment with
anti-CD8 Ab or control antibodies. (B) Intracellular cytokine staining data showed that anti-CD8 Ab-treated BCG-vaccinated macaques exhibited an
absence of PPD-specific IFNc-producing CD8 T cells early after M. tuberculosis infection.
doi:10.1371/journal.ppat.1000392.g001
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withdepletinganti-CD8Ab,andtwowithisotypecontrolIgGatthe
time of re-infection with 3000 CFU M. tuberculosis by aerosol. The
CD8 Ab-treated but not isotype IgG-treated macaques showed
profound depletion of CD8 lymphocytes in the blood and BAL fluid
(Fig. 4A). Importantly, the CD8 Ab-treated macaques with CD8
depletion showed much higher levels of M. tuberculosis burdens in
BAL fluid and lung tissues than the IgG-treated control macaques
(Fig. 4B). The gross pathology studies showed the isotype IgG-
treated macaques displayed no or limited numbers of small non-
caseating granulomas (Fig. 4C). In contrast, the CD8-depleted
macaquesshoweddisseminationof.0.5 cmcoalescingorcaseating
granulomas or tubercle nodules in both lungs (Fig. 4C). When such
tuberculosis lesions were scored using the scoring system as
described [41] in these individual macaques, the lesions scores of
CD8-depleted macaques were significantly worse than the isotype
IgG-treated controls (p,0.01, by nonparametric student t test).
Consistently, histologic analyses revealed that granulomas in the
Figure 3. Depletion of CD8 lymphocytes in CD8 Ab-treated macaques resulted in a significant decrease in BCG vaccine-induced
immunity against tuberculosis after M. tuberculosis infection. (A) Top-panel photos show that the isotype IgG-treated BCG-vaccinated
macaque (7406) exhibited limited numbers of granulomas (small arrows) in the cut-section of the right caudal lobe; the CD8 Ab-treated macaque
(7348) showed extensive tuberculosis granulomas (large arrows) in the right caudal lobe, with a unilaterally enlarged hilar lymph node (a large green
arrow). A naı ¨ve macaque (7419) showed large extensive tuberculosis lesions with caseation (large arrows), and much larger bilateral hilar lymph
nodes (large green arrows). Middle- and bottom-panel photos show tuberculosis lesions in cut-sections of lungs of six monkeys in three respective
groups. Extent and severity of the lesions could be adjudged based on the examples pointed by arrows at the top panel photos. Overall, CD8 Ab-
treated macaques exhibited greater numbers of lung lobes displaying extensive coalescing granulomas than isotype IgG-treated control animals
(p,0.05, by nonparametric t test). The CD8 Ab-treated macaques also showed more lobes with extensive caseating and miliary lesions or caseation
pneumonia than the isotype IgG-treated controls (p,0.05, by nonparametric t test). Tuberculosis lesions in the CD8 Ab-treated macaques were more
likely distributed or disseminated in other lobes or opposite lungs and hilar nodes/pleural. Small vertical/horizontal bars at bottom-left corner of each
photo represent the 1-cm scale derived from the fluorescence rulers of each original photo. (B) Gross pathology scores of tuberculosis lesions in CD8
Ab-treated group, Isotype control IgG-treated group and naı ¨ve saline-treated group of macaques. Each macaque was given a total gross pathology
scores based on the tuberculosis lesions in thoracic and extrathoracic organs. The mean gross pathology score was then calculated for each group of
macaques and subjected to statistical analysis. *, P,0.05 (by ANOVA and nonparametric t test) for comparison between CD8 Ab-treated and isotype
control IgG-treated groups, and for comparison between CD8 Ab-treated and naı ¨ve groups. (C) Histology evaluation of lung tissue sections of CD8
Ab-treated, isotype control IgG-treated and naı ¨ve saline-treated macaques. Shown are H&E stained sections taken from four representative macaques
for each group, with macaque ID and magnification indicated for each image. Note that the isotype control IgG-treated macaques exhibited well-
contained granulomas, which were generally infiltrated by numerous lymphocytes and some neutrophils. The CD8-depleted macaques displayed
less-contained granulomas that were more likely to be necrotic (arrows). Naı ¨ve macaques showed less lymphocytic and more necrotic tuberculosis
lesions than the other two groups.
doi:10.1371/journal.ppat.1000392.g003
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necrotic in the center, whereas those in the isotype IgG-treated
macaques with CD8 intact were small and highly lymphocytic
without apparent necrosis (Fig. 4D). These results from M.
tuberculosis-immunized, drug-treated macaques provided novel
evidence suggesting that M. tuberculosis-elicited CD8 T cells are
important for memory protection against tuberculosis after M.
tuberculosis re-infection.
Discussion
Our findings in BCG-vaccinated and M. tuberculosis-immunized
macaques strongly support the hypothesis that CD8 T cells play a
critical role in host defense against tuberculosis despite that the
role of CD32CD8+ cells cannot be completely ruled out.
Although the depletion of other cells expressing CD8 in addition
to CD8 memory T cells could potentially have contributed to the
observed effects of anti-CD8 treatment, this seems unlikely for
several reasons. First of all, the anti-CD8 effect was manifested as a
loss of immunological memory induced by previous BCG
immunization or M. tuberculosis infection, and such memory is a
characteristic of CD8 T cells but not of other cells known to
express CD8 such as NK cells. In addition, most macaque
dendritic cells, like their human counterparts, do not express CD8
[42], and thus immune responses of these cells in tuberculosis
might not be affected directly by the antibody-mediated CD8
Figure 4. Depletion of CD8 lymphocytes in macaques immunized by previous M. tuberculosis infection resulted in a loss of immune
control of tuberculosis following re-infection. (A) Anti-CD8 Ab treatment of the M. tuberculosis-immunized macaques resulted in profound
depletion of CD8 lymphocytes in M. tuberculosis re-infection. Shown are absolute levels of blood CD8 cells (/ul) and BAL fluid CD8 cells (650,000). (B)
Depletion of CD8 lymphocytes in the M. tuberculosis-immunized macaques led to higher levels of bacilli in BAL fluids and increased M. tuberculosis
RNA in tissues following M. tuberculosis re-infection by aerosol. Numbers of bacilli are shown as CFU counts in 10 ml of BAL fluid; M. tuberculosis RNA
was determined as Ag85B RNA copy numbers in 10 mg of tissue [6,29,36]. (C) The CD8 Ab-treated macaques with CD8 depletion developed severe
forms of tuberculosis after M. tuberculosis re-infection by aerosol. Macaque ID are indicated for CD8 Ab-treated (right) and isotype control IgG-treated
(left) macaques. Shown are the lung surface images of two representative macaques (partially cut in the lung of macaque 2762). Note that the CD8
Ab-treated macaques exhibited pale-colored lungs with dissemination of .0.5 cm coalescing or caseating granulomas or tubercle nodules (the
lesion-containing areas are pointed out by large arrows on surface view from 3050) and apparent caseation necrosis. The control macaques displayed
no or few small non-caseating granulomas as indicated by small arrows in the lungs. When .0.5 cm coalescing or caseating tubercle nodules both
lungs were scored using the scoring system as described in Methods and [41] for the individual macaques, the pathology scores (mean6SD=72624)
of the CD8-depleted macaques were significantly worse than those (mean6SD=662) of the control animals (p,0.01, by nonparametric t test). (D)
Histology of representative granulomas seen in CD8 Ab-treated (right panel) and isotype control IgG-treated (left panel) macaques. Shown are H&E
stained lung sections, with macaque ID and magnification indicated in each slide. Note that granulomas in isotype IgG-treated macaques were small,
and highly lymphocytic without apparent necrosis. Granulomas in CD8 Ab-treated macaques were large and less lymphocytic, with necrosis seen in
the center as pointed out by arrows.
doi:10.1371/journal.ppat.1000392.g004
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potentially other CD8+ cells that do not express TCR/CD3 was at
most partial by the anti-CD8 treatment in contrast to the depletion
of CD8 T cells which was essentially complete for 3–4 weeks after
infection. The memory CD8 T cells conferring anti-tuberculosis
immunity in BCG- and M. tuberculosis-immunized macaques may
include at least three different CD8 T cell subpopulations: (i)
peptide-specific classical MHC class I-restricted CD8 T cells; (ii)
non-classical MHC class I-restricted CD8 T cells [43]; (iii) lipid-
specific CD1-restricted CD8 T cells [44]. They may also include
phosphoantigen-specific Vc2Vd2 T cells, the cd T-cell subset
existing only in primates, since macaque Vc2Vd2 T cells can
express CD8 and exhibit anti-microbial responses during clonal
activation/expansion [45]. The relative importance and protective
surrogate markers of these different CD8 T cell subpopulations to
anti-tuberculosis immunity is currently not known. However, it is
noteworthy that only the first of these three populations is present
in mice, whereas all three are present in humans. For this reason,
studies such as those reported here in nonhuman primates may
reveal important activities of CD8 T cells that are not apparent in
mouse models of tuberculosis.
Our studies add to a growing body of evidence that supports the
view that CD8 T cells are of critical importance for effective
immunity against M. tuberculosis. Mycobacterium-specific CD8 T cells
have been shown to possess effector functions that are likely to
assist in the containment and clearance of M. tuberculosis, including
cytolytic effector function, cytokine production and direct
antimicrobial activity through the production of anti-microbial
peptides such as granulysin [31,46,47]. Even in mice and other
rodents which may lack some of the important recognition and
effector activities of CD8 T cells in primates, it is noteworthy that
studies have shown that approaches to vaccination that augment
CD8 T cell responses can provide better protection against
challenge with M. tuberculosis than what is achieved with standard
BCG vaccination [48]. Such findings, together with the results of
the current study, strongly suggest that CD8 T cells should be
considered as relevant targets in the design and development of
new tuberculosis vaccines and immunotherapeutics.
Methods
Macaque animals
A total of 22 monkeys were included in these studies. 18
Chinese rhesus (Macaca mulatta), 4–7 years old, were used to assess
CD8 T cells for BCG vaccine-induced immunity; 4 juvenile Indian
rhesus monkeys, 2.9 years old, were used for evaluating M.
tuberculosis-immunized CD8 T cells. Studies using all the animals
were documented in animal protocols and approved by IACUC.
BCG vaccination
12 Chinese rhesus monkeys were vaccinated intradermally with
50610
6 CFU of BCG Danish (FDA stock), as previously described
[33]. 4 months after the vaccination, the monkeys were randomly
assigned to CD8 Ab- and isotype IgG-treated groups.
M. tuberculosis immunization and anti-tuberculosis drug
treatment
Four Indian rhesus monkeys were first vaccinated with BCG,
and then challenged with 400 CFU of M. tuberculosis by aerosol as
previously described [6]. These vaccinated monkeys survived fatal
tuberculosis during a 2.5-month follow-up, whereas four control
naı ¨ve animals became moribund and had to be euthanized due to
the development of fatal tuberculosis within 1.5 moths after the
infection [6]. These M. tuberculosis-exposed monkeys with transient
low levels of bacillus but no evidence of active tuberculosis were
treated daily for 3 months with anti-TB drugs; Isoniazid (5mg/kg)
and Pyrazinamide (15mg/kg) mixing with yoga as previously
described [49], and then rested subsequently for 2 months. M.
tuberculosis infection appeared to be ‘‘cured’’ by the antibiotics,
since repeated lung washings showed no evidence of detectable
bacillus organisms; clinical follow-up demonstrated no evidence of
clinical tuberculosis. Two of these monkeys were randomly
assigned for anti-CD8 Ab treatment, and the other two assigned
for treatment with isotype IgG at the time they were re-infected
with 3000 CFU M. tuberculosis by aerosol.
Anti-CD8 antibody (Ab) treatment for depletion of CD8
lymphocytes
For the CD8 Ab-treated group, each monkey was injected
intravenously with depleting anti-CD8 Ab cM-T807 [37] at days
0, 3, 7 and 10 at doses of 10 mg/kg, 5 mg/kg, 5 mg/kg and
5 mg/kg, respectively. For the isotype control group, each monkey
was similarly injected with human IgG at same doses. For the
naı ¨ve control group, each monkey was injected similarly with
saline.
M. tuberculosis infection
At day 0, each monkey in BCG groups and the naı ¨ve group was
infected with 3000 CFU of M. tuberculosis Erdman (the standard
challenge stock from FDA) by the bronchoscope-guided injection
of the inoculum into the right caudal lobe as previously described
[29,33]. For M. tuberculosis-immunized monkeys treated with anti-
tuberculosis drugs, M. tuberculosis re-infection was introduced by
aerosol challenge with about 3000 CFU M. tuberculosis organisms
as previously described [6]. The Inhalation Exposure System used
to conduct the aerosol exposure tests was enclosed within a Class
III biological safety cabinet. A modified Microbiological Research
Establishment type three-jet Collison nebulizer (BGI, Waltham,
MA) with a precious fluid jar was used to generate a controlled
delivery of M. tuberculosis aerosol (1–1.5 um diameter of droplets)
from a PBS suspension. 10
6 M. tuberculosis CFU/ml were placed in
the nebulizer and monkeys were exposed for 10 min. Samples of
the aerosol were collected using all-glass impingers for analyzing
M. tuberculosis concentration (CFU/ml). The inhaled doses were
determined based on the AGI concentration, sampler volume,
sampling rate and respiratory minute volume of individual
macaques. The inhaled doses for the individual monkeys ranged
from 2800 to 3100 CFU of M. tuberculosis.
Bronchoalveolar lavage (BAL)
Prior to BAL, animals were subjected to overnight or 24 h
fasting, and were tranquilized i.m. with 1–2 mg/kg xylazine (Ben
Venue Laboratories, Bedford, OH) and 10 mg/kg ketamine HCl.
For BAL, animals also received 0.05 mg/kg atropine (Phoenix
Scientific, Inc., St. Joseph, MO) i.m. as an anticholinergic and
were restrained in an upright position. A pediatric feeding tube
was inserted down the larynx, into the trachea through direct
visualization with a laryngoscope to the level of the carina. 10 ml
of saline were instilled into the trachea and immediately
withdrawn and repeated a maximum of 3 times until a total of
12–15 ml BAL fluid was retrieved.
Isolation of single cell suspensions and lymphocytes from
blood and tissues
PBL were isolated from EDTA blood of the monkeys using
Ficoll/diatrizoate gradient centrifugation. Lymph nodes and
spleen were carefully teased to generate single-cell suspensions.
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RPMI medium, as previously described [29], to collect single cell
suspensions (mainly lymphocytes and tissue macrophages). The
single cells suspensions from these non-lymphoid organs were
divided into three parts: one directly used for mycobacterial CFU
counts; one directly saved as pellets for real time quantitation of M.
tuberculosis Ag85B RNA; one subjected to isolation of lymphocytes
by Ficoll/diatrizoate gradient centrifugation for flow cytometry-
based analyses of T cells.
Lymphocyte phenotying and flow cytometry analyses
Cell surface phenotyping, antibodies used for staining and flow
cytometry analyses were described as we previously published
[6,33,45]. PBMC, BAL, and tissue cells were stained with up to 5
Abs (conjugated to FITC, PE, allophycocyanin, pacific blue, and
PE-Cy5 or allophycocyanin-Cy7) for at least 15 min. After
staining, cells were fixed with 2% formaldehyde-PBS (Protocol
Formalin, Kalamazoo, MI) prior to analysis on a CyAn ADP flow
cytometer (DakoCytomation, Carpinteria, CA). Lymphocytes
were gated based on forward- and side-scatters, and pulse-width
and at least 40,000 gated events were analyzed using Summit Data
Acquisition and Analysis Software (DakoCytomation). Absolute
cell numbers were calculated based on flow cytometry data and
complete blood counts performed on a hematology system (Advia
120, Siemens, Tarrytown, NY).
Intracellular cytokine staining (ICS) measuring of
mycobacterium-specific T cells
This was done as previously described [33,36,50]. 10
5–10
6 BAL
cells or 10
6 PBL plus costimulatory mAbs CD28 (1 mg/ml) and
CD49d (1 mg/ml) were incubated with PPD (25ug/ml) or media
alone in 200 ml final volume for 1 h at 37uC, 5% CO2 followed by
an additional 5 h incubation in the presence of brefeldin A
(GolgiPlug, BD). After staining cell-surface CD3, CD4, and CD8
for 30 min, cells were permeabilized for 45 min (Cytofix/
cytoperm, BD) and stained another 45 min for IFNc and perforin
before resuspending in 2% formaldehyde-PBS.
Bacterial colony forming units (CFU) counts
Quantitation of M. tuberculosis infection was done by measuring
bacterial colony counts, as previously described [6,29,50]. To
objectively measure CFU in lungs, a half of cut-sections of the
right caudal lobe (the infection site), the right middle lobe or the
left caudal lobe from each animal were taken for CFU
determination after the extensive gross pathologic evaluation was
accomplished. If there were tuberculosis lesions in the respective
lobe, a half of the lung tissue containing approximately 50%
lesions was taken. If no visible lesions were seen in the respective
lobe, a random half of tissue was taken for evaluation. Tissue
homogenates were made using a homogenizer (PRO 200, PRO
Scientific INC, CT) and diluting the homogenate in sterile PBS +
0.05% Tween-80. 5-fold serial dilutions of samples were plated on
Middlebrook 7H11 supplemented with OADC (10%), glycerol
(0.5%), Casamino acids (0.2%; Becton Dickinson 223120), Lysine
(80 mg/L; Sigma L8662), Pantothenate (24 mg/L; Sigma P5710),
Polymyxin B (50,000 units/L; Sigma P1004), Amphotericin B
(5 mg/L; Sigma A2942), Nalidixic acid (20 mg/L; Sigma N4382),
Trimethoprim (5 mg/L; Sigma T7883) and Azlocillin (5 mg/L;
Sigma A7926). The plates were then incubated in a 37uC
incubator for 3 weeks, and CFU were counted. The minimal
detection level of vial mycobacteria is about 2 CFU on a plate
from 100 ul of 10 ml lung homogenate. The bronchoaleveolar
lavage fluid was decontaminated with the MycoPrep solutions
(Becton Dickinson cat 240862) and then plated on the supple-
mented Middlebrook 7H11.
The real time quantitative PCR for quantitation of M.
tuberculosis Ag85B RNA
The method and validation including detection limit, CV and
relationship to bacterial colony counts were previously described
[expression levels of b-actin in cells were verified and expressed as
copies of M. tb RNA in 10 mg-equivalent tissue cells [6,29,36]].
Gross pathologic analyses of TB lesions and scoring
systems
Complete necropsy was done by three pathologists and 2
veterinary doctors for M. tuberculosis-infected monkeys as previously
described [6,29,33]. Animals were sacrificed by intravenous
barbiturate overdose, and immediately necropsied in a biological
safety cabinet within a BSL-3 facility. Standard gross pathologic
evaluation procedures were followed, with each step recorded and
photographed. Multiple specimens from all tissues with gross
lesions and remaining major organs were harvested. Specifically,
each lobe of lung, bronchial, mesenteric, axillary and inguinal
lymph nodes, tonsils, and other major organs were collected and
labeled. Gross observations including but not limited to the
presence, location, size, number and distribution of lesions were
recorded. Two scoring systems were used; one system [28,29] was
used for scoring TB lesions in lungs infected by bronchoscope-
guided inoculation. For each lobe of lung, granuloma prevalence
was scored 0 -4 for (i) no visible granulomas, (ii) 1–3 visible
granulomas, (iii) 4–10 visible granulomas, (iv) .10 visible
granulomas, and (v) miliary pattern of granulomas, respectively.
Granuloma size was scored 0 -3 for (i) none present, (ii) ,1–
2 mm, (iii) 3–4 mm, and (iv) .4 mm, respectively. Pulmonary
consolidation or atelectasis as viewed from organ exterior and cut
surfaces were scored 0 -2 for (i) absent, (ii) present focally in one
lobe, and (iii) focally extensive within a lobe or involving multiple
lobes. One score was also given for the presence of tuberculosis-
related focal parietal pleural adhesions, pleural thickening and
opacification, and pulmonary parenchymal cavitation. For hilar
lymph nodes, enlargements were scored 0 -3 for (i) visible but not
enlarged, (ii) visibly enlarged unilaterally (#2cm), (iii) visibly
enlarged bilaterally (#2 cm), (iv) visibly enlarged unilaterally or
bilaterally .2 cm, respectively. Tuberculosis lesions in hilar lymph
nodes were scored 0 -4 for (i) no granulomas visible on capsular or
cut surface, (ii) focal or multifocal, circumscribed, non-coalescing
granulomas, ,2mm ($nodes), (iii) coalescing solid or caseating
granulomas occupying,50% of nodal architecture ($nodes), (iv)
coalescing solid or caseating granulomas occupying .50% of
nodal architecture, with residual nodal components still recogniz-
able, and (v) complete granulomatous nodal effacement and
caseation, respectively. One score was also given for tuberculosis-
associated changes in other thoracic nodes. The tuberculosis
lesions in each extrathoracic organ were scored similarly as each
lung lobe. The pathology scoring of infected tissues was conducted
in a blinded fashion by the senior pathologist D.H. The other
scoring system, as described [41], was adopted for scoring
.0.5 cm tubercles’ involvement in each lobe of lungs infected
by aerosol. Score 0 if no lung lobe involved; score 1 if ,J of lobe
involved; score 2 if J–K of lobe involved; score 9 if .K but ,
entire lobe involved; score 16 if entire lobe involved.
Microscopic analyses of TB lesions and acid-fast staining
Adjacent blocks of tissues were collected and fixed in buffered
10% formalin with ionized zinc (Z-Fix
TM; Anatech, LTD, Battle
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ature (OCT) compound (Sakura Finetek USA, Inc, Torrance,
CA). Histologic specimens were embedded in paraffin and
sectioned at 5um for routine staining with hematoxylin and eosin
(H&E) and selected staining with Ziehl-Neelsen acid fast stain. The
extent of lung involvement for each lung lobe was determined
using digital scans of each lobe of lung to record total pixel counts
on H&E stained material and specimen area measured in square
cm using Image-Pro Plus software (MediaCybernetics, Silver
Spring, MD). Granulomas were objectively compared for the size,
type of granuloma (caseous, solid, suppurative, or mixed),
distribution pattern (focal, multifocal, coalescing, and invasive),
and cellular composition (absence or presence with degree of
lymphocytic cuff, mineralization, fibrosis, multinucleated giant
cells, and epithelioid macrophages) between and within monkey
groups.
Statistical analysis
The multivariate analysis of variance (ANOVA) and nonpara-
metric student t test were used, as previously described [29,33,36],
to statistically analyze the data for differences in T cell numbers,
M. tuberculosis burdens, gross pathology scores or specific lesion
sizes between CD8 Ab-treated and isotype IgG-treated or naı ¨ve
control groups.
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